Antithymocyte immunoglobulin (rabbit)
- Generic Name
- Antithymocyte immunoglobulin (rabbit)
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 308067-60-9
- Unique Ingredient Identifier
- D7RD81HE4W
- Background
Rabbit anti-thymocyte globulin. Thymoglobulin is a polyclonal antibody that suppresses certain types of immune cells responsible for acute organ rejection in transplant patients. Thymoglobulin is a mixture of antibodies intended to bind to various cell surface antigens. The most common mode of action of Thymoglobulin is via selective depletion of T-cells.
- Indication
For prevention of renal transplant rejection
- Associated Conditions
- Rejection Acute Renal
- Associated Therapies
- -
MT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Severe Aplastic Anemia and Other Forms of Acquired Bone Marrow Failure.
- Conditions
- Interventions
- First Posted Date
- 2024-05-14
- Last Posted Date
- 2024-06-10
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 60
- Registration Number
- NCT06412497
- Locations
- 🇺🇸
University of Minnesota Masonic Cancer Center, Minneapolis, Minnesota, United States
1 Vs 7 RATG Infusions in Renal Transplantation
- First Posted Date
- 2024-04-18
- Last Posted Date
- 2024-11-28
- Target Recruit Count
- 75
- Registration Number
- NCT06374095
- Locations
- 🇮🇹
ASST HPG23 - Unità di Nefrologia, Bergamo, BG, Italy
A Dose Escalation Study of TCD601 Compared to ATG in de Novo Renal Transplantation
- Conditions
- Interventions
- First Posted Date
- 2024-04-15
- Last Posted Date
- 2024-07-18
- Lead Sponsor
- ITB-Med LLC
- Target Recruit Count
- 40
- Registration Number
- NCT06365437
- Locations
- 🇸🇪
Skåne University Hospital, Malmö, Sweden
🇸🇪Sahlgrenska University Hospital, Göteborg, Sweden
🇦🇹Innsbruck Medical University, Innsbruck, Austria
Sirolimus+Abatacept+Mycophenolate Mofetil for Prophylaxis of aGVHD in Patients Receiving Haplo-HSCT Who Are Intolerant to Calcineurin Inhibitors
- Conditions
- Interventions
- First Posted Date
- 2024-02-28
- Last Posted Date
- 2024-03-21
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 6
- Registration Number
- NCT06279494
ATG Plus Low-dose PT-Cy for GVHD Prevention
- First Posted Date
- 2023-10-31
- Last Posted Date
- 2024-03-21
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 196
- Registration Number
- NCT06108739
- Locations
- 🇨🇳
Peking University People's Hospital, Beijing, China
Pediatric Induction Therapy in Kidney Transplantation
- Conditions
- Interventions
- First Posted Date
- 2023-10-17
- Last Posted Date
- 2023-10-17
- Lead Sponsor
- Gang Chen
- Target Recruit Count
- 958
- Registration Number
- NCT06087003
- Locations
- 🇨🇳
The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
🇨🇳Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology, Wuhan, China
🇨🇳The First Affiliated Hospital of Sun Yat-sen University., Guangzhou, Guangdong, China
Phase III Study Comparing GVHD Prophylaxis With ATG-thymoglobulin to ATLG-grafalon in Elderly Patients With Acute Myeloid Leukemia or Myelodysplasic Syndrome and Receiving an Allogeneic Hematopoietic Stem Cell Transplantation With a 10/10 HLA Matched Unrelated Donor
- First Posted Date
- 2023-10-13
- Last Posted Date
- 2023-10-13
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 324
- Registration Number
- NCT06083129
Conditioning Regimen Containing Low Dose ATG for The Treatment of Acquired SAA Receiving sUCBT
- First Posted Date
- 2023-09-15
- Last Posted Date
- 2023-10-24
- Lead Sponsor
- Anhui Provincial Hospital
- Target Recruit Count
- 72
- Registration Number
- NCT06039436
- Locations
- 🇨🇳
The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital), Hefei, Anhui, China
CsA+ATG+AVA vs. CsA+AVA for the Treatment of Newly-diagnosed SAA in the Elderly
- Conditions
- Interventions
- First Posted Date
- 2023-08-18
- Last Posted Date
- 2023-08-18
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT05996393
- Locations
- 🇨🇳
Peking union medical college hospital, Beijing, China
Study Comparing the Efficacy of 2 RIC Regimens (Clofarabine vs Fludarabine) in Adults With AML Eligible to Allo-SCT
- Conditions
- Interventions
- First Posted Date
- 2023-06-23
- Last Posted Date
- 2023-11-15
- Lead Sponsor
- Nantes University Hospital
- Target Recruit Count
- 302
- Registration Number
- NCT05917405
- Locations
- 🇫🇷
CRLC Caen, Caen, France
🇫🇷CHU Limoges, Limoges, France
🇫🇷CHU Besançon, Besançon, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.